ETF市场日报 | 创新药相关ETF再受消息提振！能源板块回调显著

Market Overview - On July 28, 2025, A-shares saw collective gains across the three major indices, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.44%, and the ChiNext Index by 0.96%. The total trading volume in the Shanghai and Shenzhen markets exceeded 1.7 trillion yuan [1]. Innovation Drug Sector - Innovation drug-related ETFs led the market with significant gains, including the Innovation Drug ETF Hong Kong-Shenzhen (159622) rising by 4.10%, and the Hong Kong Innovation Drug 50 ETF (513780) increasing by 4.04% [1]. - A notable announcement from Heng Rui Medicine involved a potential license-out collaboration with GlaxoSmithKline (GSK) worth up to $12.5 billion, covering a clinical-stage respiratory innovation drug and up to 11 non-clinical candidates. This news led to a surge in Heng Rui's stock, reaching a four-year high in A-shares and over 16% increase in H-shares [2]. ETF Performance - The top-performing ETFs included several innovation drug-related funds, with multiple ETFs achieving gains above 3.70% [1]. - Conversely, the energy sector faced declines, with the top ETF, the Sci-Tech Comprehensive Aluminum ETF (589300), dropping by 14.01% [3]. Trading Activity - The trading volume for the Short-term Bond ETF (211360) was the highest at 33.9 billion yuan, followed by the Silver Hua Daily ETF (511880) at 21.0 billion yuan [4]. - The turnover rate for the Benchmark National Bond ETF (511100) was the highest at 552.67%, indicating strong trading activity in this segment [5][6].